FIELD: biotechnology.
SUBSTANCE: described is an AAV capsid protein for use in an AAV vector, wherein the AAV capsid protein contains an amino acid sequence which contains at least seven contiguous amino acids of the STTLYSP sequence (SEQ ID NO: 1). Disclosed is a nucleic acid which codes the described AAV capsid protein. Disclosed is an AAV vector for use in delivering a nucleic acid into a cell, where the AAV vector contains the described AAV capsid protein. Disclosed is a method of delivering a transgene into a cell, where the method involves bringing the cell into contact with the disclosed AAV vector.
EFFECT: invention enables to express the transgene, for example, in the central nervous system, PNS, in the inner ear, in the heart or in the retina, and also enables to express the transgene in cells of the required types.
22 cl, 9 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING MODIFIED CAPSID OF ADENO-ASSOCIATED VIRUS | 2021 |
|
RU2831732C1 |
| ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| SYNERGETIC ACTION OF SMN1 AND MIR-23A IN TREATING SPINAL MUSCULAR ATROPHY | 2021 |
|
RU2839898C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
